|
|
|
| Effects of arginine human insulin injection for treating pregnant women with gestational diabetes mellitus on their blood glucose and pregnancy outcomes |
| 1.Lujiang County People's Hospital Hefei, Anhui Province, 231500; 2.The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital |
|
|
|
|
Abstract To investigate the effects of applying arginine human insulin injection for treating pregnant women with gestational diabetes mellitus (GDM) on their levels of hemoglobin (HGB), C-reactive protein (CRP), C-peptide (CP) and blood glucose, and their safety. Methods: 106 pregnant women with GDM who were admitted to hospital were selected and were divided into control group and observation group (53 cases in each group) by the two-color grouping method from December 2020 to December 2023. The women in the two groups were given the treatment of insulin aspart for treating their GDM for 2 months, the women in the control group were given the treatment of menthol insulin additionally and the women in the observation group were given the treatment of arginin-synthesized human insulin injection additionally. The levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c) and 2 h postprandial glucose (2h PG) and fasting insulin (FINS) of the women in the two groups before and after treatment were detected. The homeostasis model assessment of insulin resistance (HOMA-IR) value of the women in the two groups was calculated. The levels of the HGB, CP, CRP and interleukin-6 (IL-6) of the women in the two groups were also detected. The adverse pregnancy outcomes of the women in the two groups were collected. Results: The levels of FBG, HbAlc, 2hPG, HGB, CRP and IL-6, and the HOMA-IR value of the women in both groups after 2 months of treatment had decreased significantly, and which (4.06±0.28 mmol/L, 4.15%±0.26%, 5.05±0.36 mmol/L, 134.79±5.32 g/L, 5.01±0.12 mg/L, 6.33±0.70 ng/ml and 2.29±0.47) of the women in the observation group were significantly lower than those (5.11±0.48 mmol/L, 5.31%±0.56%, 6.46±0.38mmol/L, 138.12±9.95g/L, 6.96±0.34mg/L, 7.59±0.82ng/ml and 2.52±0.56) of the women in the control group. The levels of FINS and CP of the women in both groups had increased significantly, and which (8.61±0.38 mU/L and 1.90±0.26mg/L) of the women in the observation group were significantly higher than those (7.89±0.31mU/L and 1.67±0.22 mg/L) of the women in the control group. The incidence of the adverse pregnancy outcomes (11.3%) of the women in the observation group was significantly lower than that (32.1%) of the women in the control group (P<0.05). Conclusion: The insulin aspart combined with arginine human islet injection for treating the pregnant women with GDM can effectively improve their blood glucose level, elevate their HGB and CP levels, and reduce their levels of inflammatory factors and adverse pregnancy outcomes, and with the higher clinical effectiveness and safety.
|
|
|
|
|
|
|
|
|
